This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Widakowich, C. Articles by Awada, A. Search for Related Content PubMed PubMed Citation Articles by Widakowich, C. Articles by Awada, A.

Symptom Management and Supportive Care

Review: Side Effects of Approved Molecular Targeted Therapies in Solid Cancers

^aMedical Oncology Clinic, Institut Jules Bordet, Brussels, Belgium; ^bUniversité Libre de Bruxelles, Brussels, Belgium; ^cClinical Oncology Service, Hospital das Clinicas, University of Sao Paulo Medical School, Sao Paulo, Brazil

Key Words. Targeted therapy • Toxicity • Anti-EGFR agents • Anti-HER-2 agents • Anti-VEGFR agents

Correspondence: Ahmad Awada, M.D., Ph.D., Department of Medicine, Medical Oncology Clinic, Jules Bordet Institute, Rue Heger-Bordet, 1, 1000 Brussels, Belgium. Telephone: 32-2-541-31-89; Fax: 32-2-538-08-58; e-mail: ahmad.awada{at}bordet.be

Disclosure: No potential conflicts of interest were reported by the authors, planners, reviewers, or staff managers of this article.

Major advances have been achieved in the field of biologically based therapies for cancer in the last few years, and some of the recently approved molecular-targeted therapies are now being used in daily clinical practice. These molecular targets are also expressed in normal cells, which explains the different grades of toxicity, resulting from the disruption of normal cellular function. In general, targeted molecular therapies have good toxicity profiles, but some patients are exquisitely sensitive to these drugs and can develop particular and severe toxicities. In this article, we review the toxicity and safety of various small molecules and monoclonal antibodies used in solid tumors, with discussion of the pathophysiology, correlation with response, and strategies for prevention and management.

This article has been cited by other articles:

				L. Lee, H. Niu, R. Rueger, Y. Igawa, J. Deutsch, N. Ishii, S. Mu, Y. Sakamoto, R. Busse-Reid, C. Gimmi, et al. The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of CH4987655 in Healthy Volunteers: Target Suppression Using a Biomarker Clin. Cancer Res., December 1, 2009; 15(23): 7368 - 7374. [Abstract] [Full Text] [PDF]

				Y. Kurihara, Y. Watanabe, H. Onimatsu, T. Kojima, T. Shirota, M. Hatori, D. Liu, S. Kyo, H. Mizuguchi, Y. Urata, et al. Telomerase-Specific Virotheranostics for Human Head and Neck Cancer Clin. Cancer Res., April 1, 2009; 15(7): 2335 - 2343. [Abstract] [Full Text] [PDF]

				A. Card, C. Caldwell, H. Min, B. Lokchander, Hualin Xi, S. Sciabola, A. V. Kamath, S. L. Clugston, W. R. Tschantz, Leyu Wang, et al. High-Throughput Biochemical Kinase Selectivity Assays: Panel Development and Screening Applications J Biomol Screen, January 1, 2009; 14(1): 31 - 42. [Abstract] [PDF]

				E. Vigna, G. Pacchiana, M. Mazzone, C. Chiriaco, L. Fontani, C. Basilico, S. Pennacchietti, and P. M. Comoglio "Active" Cancer Immunotherapy by Anti-Met Antibody Gene Transfer Cancer Res., November 15, 2008; 68(22): 9176 - 9183. [Abstract] [Full Text] [PDF]